000			03357nam a22005417a 4500
008			180619s20182018 xxu||||| |||| 00| 0 eng d
022			_a1477-7819
024			_a10.1186/s12957-018-1377-7 [doi]
024			_a10.1186/s12957-018-1377-7 [pii]
024			_aPMC5952844 [pmc]
040			_aOvid MEDLINE(R)
099			_a29764445
245			_aCurrent practices of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the treatment of peritoneal surface malignancies: an international survey of oncologic surgeons.
251			_aWorld Journal of Surgical Oncology. 16(1):92, 2018 May 15.
252			_aWorld J Surg Oncol. 16(1):92, 2018 May 15.
253			_aWorld journal of surgical oncology
260			_c2018
260			_fFY2018
266			_d2018-06-19
501			_aAvailable online through MWHC library: 2003 - present
520			_aBACKGROUND: The goal of the study was to investigate the current clinical practices among oncologic surgeons regarding cytoreductive surgery (CRS) with intraoperative hyperthermic intraperitoneal chemotherapy (HIPEC).
520			_aCONCLUSIONS: Despite the fact that CRS HIPEC is the standard treatment for PSM, the clinical practices are very different according to each clinical situation. Nevertheless, mesenteric invasion was found to be the most important factor impacting the treatment decision-making by the majority of responders.
520			_aMETHODS: From September to October 2016, an online questionnaire surveyed the oncologic surgeons by email. The questionnaire included 20 multiple-choice questions of the following: eligibility for the CRS with HIPEC procedure, perioperative staging and surgery skill, assessment of residual tumors, and method used for intraperitoneal HIPEC.
520			_aRESULTS: The response rate was 16% (34/217). The majority of respondents (68%) worked at a university hospital. All respondents indicated that mesenteric invasion is the most crucial factor affecting treatment decision. Most surgeons (79%) used the Sugarbaker's staging system to intraoperatively measure the extent of peritoneal invasion. The methods used to measure the extent of miliary pattern of residual tumor spread, and the amount of residual tumor after electrocauterization varied among the surgeons. Most responders (65%) used the closed system of HIPEC.
546			_aEnglish
650			_a*Chemotherapy, Cancer, Regional Perfusion/mt [Methods]
650			_a*Cytoreduction Surgical Procedures/mt [Methods]
650			_a*Hyperthermia, Induced/mt [Methods]
650			_a*Peritoneal Neoplasms/th [Therapy]
650			_a*Practice Patterns, Physicians'
650			_a*Surveys and Questionnaires
650			_aAdult
650			_aFemale
650			_aHumans
650			_aInternational Agencies
650			_aMale
650			_aMiddle Aged
650			_aPeritoneal Neoplasms/pa [Pathology]
650			_aPrognosis
650			_aSurgeons/sn [Statistics & Numerical Data]
650			_aSurvival Rate
651			_aMedStar Heart & Vascular Institute
657			_aJournal Article
700			_aHong, Jenny
790			_aHan HY, Hong JJ, Kim Y, Ko YB, Lee M, Lim MC, Park SY, Song YJ, Yoo HJ
856			_uhttps://dx.doi.org/10.1186/s12957-018-1377-7 _zhttps://dx.doi.org/10.1186/s12957-018-1377-7
942			_cART _dArticle
999			_c3415 _d3415